The platform integrates multimodal imaging with single-cell analysis to detect and profile rare cells, focusing initially on hematologic cancers and the monitoring of cell and gene therapies. By uncovering actionable data from these scarce cellular populations, the company aims to establish Rare-Cell Biology as a standard discipline for clinical diagnostics and drug development.

Sasha Bakhru, Managing Partner at 108 BioCapital, noted that the platform’s capacity to characterize rare cells could fundamentally alter how clinicians track disease progression and patient responses. Following this investment, CellsBin intends to grow its technical and scientific teams while broadening its network of strategic healthcare partnerships to solidify its market presence.